Skip to content

Assessment of ONS-flavour Preference in Cancer Patients With and Without Taste Alterations

Assessment of ONS-flavour Preference in Cancer Patients With and Without Taste Alterations

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05518825
Acronym
PREFER
Enrollment
64
Registered
2022-08-29
Start date
2022-10-06
Completion date
2023-03-28
Last updated
2023-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncology, Taste, Altered

Keywords

Oral nutritional supplement, Oncology, Taste alterations

Brief summary

A single arm intervention study examining ONS-flavour preference in cancer patients with and without taste alterations

Interventions

DIETARY_SUPPLEMENTFortimel/Nutridrink Compact Protein

Twice daily serving of the study product

Sponsors

Nutricia Research
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Being diagnosed with cancer 2. Undergoing, or having undergone systemic anti-cancer treatment or radiotherapy in the past 12 months. 3. Age \> 18 years 4. Written informed consent

Exclusion criteria

1. Taste and smell alterations not caused by the cancer or anti-cancer treatment 2. Galactosaemia 3. Use of thickener to be able to swallow safely 4. Allergies to any of the product ingredients or any of the flavours 5. Current prescription for ONS, enteral nutrition or parenteral nutrition 6. Diabetes mellitus Type I or Type II 7. Open sores or severe inflammation in the mouth or throat 8. Undergoing dialysis 9. Hepatic encephalopathy 10. Patients with heart failure who have symptoms of heart failure at rest and/or are unable to carry on any physical activity without discomfort 11. Known pregnancy or lactation 12. Average alcohol use of \> 21 glasses per week for men or \> 14 glasses per week for women or drug abuse in opinion of the investigator 13. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements 14. Participation in any other studies involving food products concomitantly or within two weeks prior to entry into the study. 15. Employees of Nutricia Research and/or partners, parents, children and brothers/sisters of employees

Design outcomes

Primary

MeasureTime frameDescription
Choice for the Fortimel/Nutridrink Compact Protein sensation flavour over the Fortimel/Nutridrink Compact Protein regular flavourOn 4 daysSubjects take one sensation flavour and one regular flavour and are asked in a direct question which flavour they prefer.

Secondary

MeasureTime frameDescription
Difference between average liking scores [score 0-10] for Fortimel/Nutridrink Compact Protein sensation flavour range versus Fortimel/Nutridrink Compact Protein regular flavour rangeOn 4 days
Choice for the Fortimel/Nutridrink Compact Protein sensation flavours over the Fortimel/Nutridrink Compact Protein regular flavours between patients with and patients without Taste and Smell AlterationsOn 4 daysSubjects take one sensation flavour and one regular flavour and are asked in a direct question which flavour they prefer.
Difference in average liking scores [score 0-10] for Fortimel/Nutridrink Compact Protein sensation flavour versus Fortimel/Nutridrink Compact Protein regular flavour between patients with and patients without Taste and Smell AlterationsOn 4 days

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026